Insider trade

CEO sold ~$1.9M of UTHR shares in the open market

Traded Jul 7, 2026 · Filed Jul 9, 2026

Why it stands out

The CEO of United Therapeutics sold $1.9M of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEO$1M+Pre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$1,902,629

Shares × reported transaction price

Timing vs results

62 days after results of May 6, 2026, 29 days before results of Aug 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
This transaction was executed in multiple trades at prices ranging from $559.30 to $560.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Filed 2mo ago

Traded Aug 6 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.

Scheduled in advanceFiled 2mo ago

Scheduled in advanceFiled 2mo ago